1181 completed, 824 unknown, 553 recruiting, 277 terminated. 1116 Phase 2, 654 Not applicable, 609 Phase 1, 317 Phase 3, 105 Phase 4.
Follow Carcinoma, Hepatocellular: new trials by email Literature Review of Carcinoma, Hepatocellular trials Research Report on Carcinoma, Hepatocellular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration RayAblation - Liver Tumors | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2027-04-01 | 2026-10-16 |
| A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma Ivonescimab - Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | MedSIR | 44 | 2027-03-01 | 2026-11-04 |
| Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus | Phase 4 | Not yet recruiting | Eunice Dube | 2140 | 2027-01-30 | 2026-07-30 |
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning. TheraSphere - Hepatocellular Carcinoma (HCC) | Not yet recruiting | Boston Scientific Corporation | 140 | 2027-01-01 | 2026-10-30 | |
| Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy Actigraphy, Online Mindfulness Meditation, Smartphone Application-based Intervention - Hepatocellular Carcinoma, Pancreas Cancer | Not applicable | Not yet recruiting | City of Hope Medical Center | 70 | 2027-01-01 | 2026-11-10 |
| A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus QL1706 (Iparomlimab/Tuvonralimab) - Hepatecellular Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 43 | 2027-01-01 | 2026-11-16 |
| Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review - Hepatocellular Carcinoma (HCC), Liver Cancer, Adult | Phase 2 | Not yet recruiting | University of California, San Francisco | 50 | 2026-12-15 | 2026-10-13 |
| Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) - Hepatocellular Carcinoma (HCC) | Phase 3 | Not yet recruiting | University Health Network, Toronto | 60 | 2026-12-01 | 2026-10-26 |
| Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma Zanzalintinib, Tegavivint - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 36 | 2026-12-01 | 2026-10-16 |
| Erlotinib for Hepatocellular Carcinoma Chemoprevention erlotinib hydrochloride, Placebo - Cirrhosis, Liver, Advanced Liver Fibrosis | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-12-01 | 2026-06-24 |
| Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma Curative-Intent Liver Resection, Immunotherapy-Based Systemic Maintenance Therapy - Hepatocellular Carcinoma | Not applicable | Not yet recruiting | West China Hospital | 60 | 2026-12-01 | 2026-10-08 |
| QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients Intervention 1 - Drug QL1706 (Iparomlimab and Tuvonralimab) Intervention 2 - Drug Lenvatinib Intervention 3 - Drug FOLFOX Chemotherapy (Oxaliplatin, Fluorouracil, and Levoleucovorin Calcium) - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 33 | 2026-12-01 | 2026-11-12 |
| 90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma Hepatocellular Carcinoma (HCC) | Not yet recruiting | Beijing Tsinghua Chang Gung Hospital | 200 | 2026-12-01 | 2026-11-17 | |
| PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC Lenvatinib, Partial transarterial chemoembolization (TACE) - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 40 | 2026-11-30 | 2026-11-03 |
| Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma BGB-B2033 - Hepatocellular Cancer, Liver Cancer | Phase 2 | Not yet recruiting | BeOne Medicines | 100 | 2026-11-30 | 2026-11-03 |
| Risk Factors and Early Predictors of Bile Leak After Major Liver Resection Major hepatectomy, Drain-fluid and serum bilirubin measurement - Bile Leak, Biliary Fistula | Not yet recruiting | Minia University | 100 | 2026-11-25 | 2026-11-19 | |
| Assessment of Patient Radiation Exposure and Development of Diagnostic Reference Levels(DRLs) Standards for Endoscopic Retrograde Cholangiopancreatography (ERCP). Choledocholithiasis, Biliary Stricture | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 150 | 2026-11-16 | 2026-11-18 |
Showing 20 of 3390. Sign in to see all of them.
Liver Neoplasms (530) · Stomach Neoplasms (153) · Neoplasms (149) · Carcinoma, Non-Small-Cell Lung (141) · Colorectal Neoplasms (137) · Carcinoma, Renal Cell (135) · Pancreatic Neoplasms (129) · Cholangiocarcinoma (116) · Melanoma (115) · Liver Cirrhosis (97) · Fibrosis (93) · Neoplasm Metastasis (92) · Esophageal Neoplasms (87) · Breast Neoplasms (83)
Neoplasms by Histologic Type (3383) · Neoplasms by Site (3382) · Adenocarcinoma (3380) · Digestive System Diseases (3380) · Neoplasms, Glandular and Epithelial (3380) · Digestive System Neoplasms (3371) · Carcinoma (3349) · Liver Diseases (3337) · Neoplasms (3241) · Liver Neoplasms (2860) · Pathological Conditions, Signs and Symptoms (486) · Pathologic Processes (444) · Gastrointestinal Diseases (284) · Gastrointestinal Neoplasms (258) · Urogenital Diseases (247)
Sorafenib (224) · lenvatinib (154) · Bevacizumab (141) · Nivolumab (91) · atezolizumab (84) · Radiosurgery (76) · pembrolizumab (76) · durvalumab (65) · sintilimab (65) · Oxaliplatin (61) · Fluorouracil (57) · tislelizumab (48) · Doxorubicin (47) · apatinib (46) · Radiofrequency Ablation (44)
Sun Yat-sen University (169) · National Cancer Institute (NCI) (75) · Seoul National University Hospital (60) · Shanghai Zhongshan Hospital (58) · Eastern Hepatobiliary Surgery Hospital (46) · Fudan University (44) · National Taiwan University Hospital (40) · Assistance Publique - Hôpitaux de Paris (39) · M.D. Anderson Cancer Center (35) · Guangxi Medical University (34) · Bayer (33) · Tianjin Medical University Cancer Institute and Hospital (30) · Second Affiliated Hospital of Guangzhou Medical University (27) · Zhejiang University (27) · Zhongda Hospital (26)
China (1163) · United States (896) · South Korea (277) · France (271) · Taiwan (262) · Italy (197) · Spain (153) · Germany (143) · Canada (122) · Hong Kong (115) · Japan (110) · United Kingdom (107) · Singapore (88) · Belgium (84) · Australia (73)
Ming Shi, MD (21) · Jeong Min Lee, MD (14) · Tim F Greten, M.D. (11) · David Hsieh, MD (7) · Gao-Jun Teng, M.D. (6)
PMID 12049862, PMID 11981766, PMID 12540794, PMID 18650514, PMID 19192962, PMID 19095497, PMID 29628281, PMID 32402160, PMID 34143971, PMID 36852452, PMID 12091661, PMID 21374666, PMID 27932229, PMID 29433850, PMID 29471013, PMID 29875066, PMID 32557715, PMID 32716739, PMID 33538338, PMID 34905388, PMID 14667750, PMID 19766639, PMID 26361969, PMID 30207593, PMID 31070690, PMID 31401903, PMID 35421228, PMID 36529152, PMID 38319892, PMID 39437804, PMID 10207464, PMID 14762851, PMID 16250051, PMID 16495695, PMID 16557381, PMID 16908937, PMID 18477802, PMID 19212170, PMID 19908093, PMID 19949018, PMID 20175033, PMID 20203173, PMID 20590903, PMID 20839057, PMID 22002018, PMID 22424438, PMID 22968066, PMID 23099728, PMID 23269991, PMID 23393196
2023 (16), 2016 (11), 2017 (10), 2018 (10), 2019 (10), P30CA016672 (10), P30CA060553 (9), 2025 (8), P30CA015083 (8), 2009 (7), 2014 (7), P30CA014089 (7), P30CA033572 (7), 2015 (6), N01CM62201 (5)